At Quoin Pharmaceuticals Ltd.’s Special General Meeting on November 12, 2026, shareholders approved raising applicable investor ownership limits from 4.99% to as much as 9.99% and authorized an adjournment if needed.
QNRX · Quoin Pharmaceuticals Ltd.
The latest filing no longer states the doubt (first flagged Aug 14, 2026).
View the 10-Q filed Nov 5, 2026You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Quoin Pharmaceuticals Ltd. reported statistically significant interim Phase 2/3 QRX003 results in Netherton Syndrome, including 66.7% achieving the primary endpoint, alongside a private placement for up to approximately $50.0 million.
Quoin reported positive interim QRX003 data in Netherton Syndrome; four of six participants achieved target 1-grade or greater improvement at week 12. It also launched a $11,000,000 ATM offering on November 4, 2026.
Quoin Pharmaceuticals Ltd. entered a sales agreement with Leerink Partners LLC on November 4, 2026, enabling at-the-market sales of ADSs, each representing 35 ordinary shares, with a 3.0% commission on gross proceeds.
Quoin Pharmaceuticals Ltd. filed a shelf registration statement allowing it to offer up to $150,000,000 in ordinary shares represented by ADSs, warrants, subscription rights, debt securities and units. As of October 23, 2026, the public float was approximately $36,422,384, and while it remains below $75.0 million, the company may not sell securities in a public primary offering exceeding more than one-third of that float in any 12-month period.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| IGA score | 0 | by eight months | — |
| initial upfront funding | $30.8M | August 28, 2026 | — |
| key secondary endpoint | 0.01 | Week 12 | — |
| NETHERTON NOW series impressions | 28M | September 10, 2026 | — |
| NETHERTON NOW series views | 2.8M | September 10, 2026 | — |
| participants with moderate to severe pruritus at baseline achieving a 3-grade or greater improve | 3 | Week 12 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QNRX
this stock
Quoin Pharmaceuticals Ltd.
|
$16.14M | -76.7% | — | — | 0.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 27
At Quoin Pharmaceuticals Ltd.’s Special General Meeting on November 12, 2026, shareholders approved raising applicable investor ownership limits from 4.99% to as much as 9.99% and authorized an adjournment if needed.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QNRX | -10.4% | -16.2% | -29.6% | -26.0% | -76.7% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -5.0% | -9.9% | -24.0% | -20.7% | -81.7% |